US Slashes Import Ban In Daewoong, Medytox Botulinum War

But Legal Maneuvering Not Over Yet

The USITC has issued a final determination in the long-running botulinum toxin dispute between Daewoong and Medytox, sharply cutting the length of Daewoong’s product import ban and reversing its initial decision with respect to Medytox’s bacterial strain. But the dispute seems poised to continue as Daewoong vows further legal steps.

ITC
Daewoong Gets Sharply Reduced Product Import Ban After USITC Ruling • Source: Shutterstock

Daewoong Pharmaceutical Company Ltd. has received a much reduced US import ban for its botulinum toxin product Jeuveau (prabotulinumtoxinA-xvfs) following a US International Trade Commission (USITC) final determination reversing an initial decision over trade secrets with respect to competitor Medytox Inc.’s bacterial strain.

The commission affirmed in part the initial determination of the Administrative Law Judge (ALJ) finding a violation of Section 337...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

Regeneron Wins PCSK9 Court Battle Against Amgen

 

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

 
• By 

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs

More from Business

BIO Notebook: IPO Window Stays Shut, PRVs Need To Be A Priority, And Focusing On Gene Therapy Safety

 

Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By 

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Supernus Secures Sage With CVR-Supported Deal

 

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.